Partner Gabor Garai was quoted in an article that appeared in the Boston Globe on May 10, 2013 titled, “Markets draw life science start-ups.” The article discussed how rebounding financial markets are attracting an increasing number of life sciences start-ups looking to raise large amounts of money through IPOs — resulting in the anticipated biggest coming-out class for life sciences since 2007. The article highlighted the risks to going public, but noted that public offerings are emerging as the financing event of choice for start-ups that do not want to give up too much control to private investors or larger industry players. Mr. Garai was quoted as saying, “When it comes to drugs, the cost of getting anything to market has become inordinate. Right now, there’s more money in the public markets chasing deals than in the venture capital markets. We’re seeing the first signs of spring after a cold winter for IPOs.”
People
Related News
June 6, 2025
In the News
David Rosen Comments on FDA, Compounder Conflict Over Drug Shortages
Foley & Lardner LLP partner David Rosen highlighted the U.S. Food and Drug Administration's drug shortage list in the BioSpace article, "Post-Chevron Legal Battles: Three Key Cases to Watch."
June 5, 2025
In the News
Michael Bennett and Zack Flagel Explore Pro Tennis Antitrust Battle
Foley & Lardner LLP attorneys Michael Bennett and Zack Flagel assess the antitrust litigation embroiling professional tennis in their LawInSport article, "Break(ing) Point? The Antitrust Battle that Could Transform Professional Tennis."
June 4, 2025
In the News
Foley Attorneys Explore IP Considerations for AI-Generated Logos
Foley & Lardner LLP attorneys Von Bryant, Norm Rich, and Alex Liederman authored the Bloomberg Law article, "AI-Generated Logos Require Careful Steps to Protect IP Rights."